Outlook Therapeutics® Gains European Commission Approval for Marketing LYTENAVA™ (bevacizumab gamma) to Treat Wet AMD.

The U.S. Food and Drug Administration has granted approval to Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab) for the treatment of specific rare conditions.

In the TROPION-Lung01 Phase III trial, datopotamab deruxtecan significantly improved overall survival compared to chemotherapy in patients with advanced nonsquamous non-small cell lung cancer.

Sarclisa received FDA priority review for treating newly diagnosed multiple myeloma patients ineligible for transplant.

TILT Biotherapeutics' one abstract highlights encouraging safety and efficacy findings of TILT-123 in patients with ovarian cancer.

selectION, Inc. declared the commencement of a Phase 1b study involving its leading candidate si-544 in adult individuals suffering from psoriasis vulgaris or psoriatic arthritis.

Novel Bispecific Antibody REGN7075 (EGFRxCD28) Shows Anti-Tumor Effects with Libtayo® (cemiplimab); Findings to be Presented at ASCO.

I-Mab Releases Promising Phase 1 Results for PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024.

BioAtla to Showcase Phase 1 Evalstotug Clinical Trial Outcomes Highlighting Clinical Benefits at the 2024 ASCO Annual Conference.

Sensei Biotherapeutics, Inc. has announced promising clinical results from the dose-escalation segment of its Phase 1/2 study on SNS-101.

Coherus BioSciences, Inc. presented results from the CHS-114 monotherapy dose escalation part of its Phase 1 trial at the ASCO Annual Meeting.

Cure Genetics Revealed Positive Safety and Effectiveness Data for CAR-NKT Treatment CGC729 in RCC at ASGCT 2024.